01 January 2009
Clinical evaluation of busulfan, cladribine and alemtuzumab as reduced intensity conditioning for stem cell transplantation
Kazimierz Halaburda, Bozena Marianska, Krzysztof Warzocha, Barbara Nasilowska-Adamska, Andrzej Szczepinski, Agnieszka Tomaszewska, Jadwiga Sawecka, Joanna SkulimowskaAnn Transplant 2009; 14(2): 7-12 :: ID: 880525
Abstract
Background: Reduced intensity conditioning before allogeneic stem cell transplantation is an option for patients not eligible for myeloablative standard procedure. In recent years alemtuzumab, an anti CD52 antibody has gained much interest in this setting for its particular immunosuppresive properties.
Material/Methods: We evaluated clinical results of allogeneic stem cell transplantation in nine patients (2 females and 7 males, median age 51, range 26-65) after reduced intensity conditioning consisting of busulfan, cladribine and alemtuzumab. The donors were HLA identical siblings (7) or unrelated (2). Peripheral blood stem cells mobilized with G-CSF were used. Cyclosporine alone was used for GvHD prevention after transplantation.
Results: 4 patients (44%) are alive at 24-42 months after transplantation and 3 patients (33%) remain in complete remission at 26-42 months, including one after donor lymphocyte infusion for decreasing hematopoietic chimerism. No acute graft versus host disease was observed and only 3 patients (33%) developed chronic graft versus host disease. High rate (56%) of CMV reactivation and 2 cases of tuberculosis were noted. All deceased patents died due to disease relapse and progression.
Conclusions: Reduced intensity conditioning with alemtuzumab and allogeneic stem cell transplantation offers potential cure to patients not eligible for conventional procedure. Better methodology of chimerism evaluation is mandatory to improve results of transplantations by implementation donor lymphocyte infusions.
Keywords: Stem Cell Transplantation, reduced intensity conditioning, alemtuzumab
In Press
08 Mar 2024 : Original article
Association of Coronary Calcium Score on Cardiac PET During Pre-Kidney Transplant Assessment with Persisten...Ann Transplant In Press; DOI: 10.12659/AOT.943532
14 Mar 2024 : Original article
Impact of Blood Products Transfusion on Patients in the Immediate Post-Lung Transplant Period: A Cohort StudyAnn Transplant In Press; DOI: 10.12659/AOT.943652
14 Mar 2024 : Case report
Treatment of Cavernous Transformation of Portal Vein Caused by Hepatic Cystic Echinococcosis Using Ex Vivo ...Ann Transplant In Press; DOI: 10.12659/AOT.942358
15 Mar 2024 : Review article
Approaches and Challenges in the Current Management of Cytomegalovirus in Transplant Recipients: Highlighti...Ann Transplant In Press; DOI: 10.12659/AOT.941185
Most Viewed Current Articles
05 Apr 2022 : Original article
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
12 Jan 2022 : Original article
Risk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of ...DOI :10.12659/AOT.934738
Ann Transplant 2022; 27:e934738
22 Nov 2022 : Original article
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
15 Mar 2022 : Case report
Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...DOI :10.12659/AOT.935860
Ann Transplant 2022; 27:e935860